
Raman Sankar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10820353/publications.pdf Version: 2024-02-01



0

#	Article	IF	CITATIONS
1	Refining epileptogenic high-frequency oscillations using deep learning: a reverse engineering approach. Brain Communications, 2022, 4, fcab267.	1.5	14
2	Knowledge gaps for functional outcomes after multilobar resective and disconnective pediatric epilepsy surgery: Conference Proceedings of the Patientâ€Centered Stakeholder Meeting 2019. Epileptic Disorders, 2022, 24, 50-66.	0.7	4
3	Susceptibility to epilepsy after traumatic brain injury is associated with preexistent gut microbiome profile. Epilepsia, 2022, 63, 1835-1848.	2.6	13
4	Value of genetic testing for pediatric epilepsy: Driving earlier diagnosis of ceroid lipofuscinosis type 2 Batten disease. Epilepsia, 2022, 63, .	2.6	6
5	Potential induction of epileptic spasms by nonselective voltage-gated sodium channel blockade: Interaction with etiology. Epilepsy and Behavior, 2021, 115, 107624.	0.9	10
6	Diversity of kindling of limbic seizures after lateral fluid percussion injury in the rat. Epilepsia Open, 2021, 6, 413-418.	1.3	2
7	Disruption of intestinal barrier and endotoxemia after traumatic brain injury: Implications for postâ€ŧraumatic epilepsy. Epilepsia, 2021, 62, 1472-1481.	2.6	23
8	Synthetic pharmaceutical grade cannabidiol for treatment of refractory infantile spasms: A multicenter phase-2 study. Epilepsy and Behavior, 2020, 102, 106826.	0.9	21
9	Long-term safety and tolerability of adjunctive eslicarbazepine acetate in children with focal seizures. Epilepsy and Behavior, 2020, 112, 107458.	0.9	2
10	Scalp EEG interictal high frequency oscillations as an objective biomarker of infantile spasms. Clinical Neurophysiology, 2020, 131, 2527-2536.	0.7	31
11	The Natural History of Epilepsy. , 2020, , 1-13.		0
12	Challenges in Identifying Medication-Resistant Epilepsy. , 2020, , 14-19.		0
13	International League Against Epilepsy's Definition of Medication-Resistant Epilepsy. , 2020, , 20-26.		0
14	The Economic Impact of Medication-Resistant Epilepsy. , 2020, , 27-33.		0
15	Social Consequences of Medication-Resistant Epilepsy. , 2020, , 34-38.		0
16	Mortality and Morbidity of Medication-Resistant Epilepsy. , 2020, , 39-50.		0
17	Models for Medication-Resistant Epilepsy. , 2020, , 51-61.		0

18 Neurobiology of Medication-Resistant Epilepsy. , 2020, , 62-68.

2

#	Article	IF	CITATIONS
19	Genetic Causes of Medication-Resistant Epilepsy. , 2020, , 69-78.		Ο
20	Malformations of Cortical Development as Causes of Medication-Resistant Epilepsy. , 2020, , 79-86.		0
21	Hippocampal Sclerosis as a Cause of Medication-Resistant Epilepsy. , 2020, , 87-99.		Ο
22	Autoimmune Causes of Medication-Resistant Epilepsy. , 2020, , 100-117.		0
23	Medication-Resistant Epilepsy Syndromes in Children. , 2020, , 118-157.		Ο
24	Medication-Resistant Epilepsy in Adults. , 2020, , 158-170.		1
25	Approach to the Treatment of Medication-Resistant Epilepsy. , 2020, , 171-178.		О
26	Pharmacotherapy for Medication-Resistant Epilepsy. , 2020, , 179-186.		2
27	Reproductive Health for Women with Medication-Resistant Epilepsy. , 2020, , 187-197.		Ο
28	Resective Surgery for Medication-Resistant Epilepsy. , 2020, , 198-209.		0
29	Ablative Surgery for Medication-Resistant Epilepsy. , 2020, , 210-218.		Ο
30	Stimulation Treatment for Medication-Resistant Epilepsy. , 2020, , 219-240.		0
31	Diet Therapy for Medication-Resistant Epilepsy. , 2020, , 241-247.		Ο
32	Botanical Treatments for Medication-Resistant Epilepsy. , 2020, , 248-255.		0
33	Psychiatric Comorbidities in Medication-Resistant Epilepsy. , 2020, , 256-268.		Ο
34	Limited efficacy of zonisamide in the treatment of refractory infantile spasms. Epilepsia Open, 2020, 5, 121-126.	1.3	8
35	Felbamate in the treatment of refractory epileptic spasms. Epilepsy Research, 2020, 161, 106284.	0.8	7
36	Interictal scalp fast ripple occurrence and high frequency oscillation slow wave coupling in epileptic spasms. Clinical Neurophysiology, 2020, 131, 1433-1443.	0.7	18

#	Article	IF	CITATIONS
37	Possible precision medicine implications from genetic testing using combined detection of sequence and intragenic copy number variants in a large cohort with childhood epilepsy. Epilepsia Open, 2019, 4, 397-408.	1.3	68
38	Very-High-Dose Prednisolone Before ACTH for Treatment of Infantile Spasms: Evaluation of a Standardized Protocol. Pediatric Neurology, 2019, 99, 16-22.	1.0	14
39	Melanotan-II reverses autistic features in a maternal immune activation mouse model of autism. PLoS ONE, 2019, 14, e0210389.	1.1	16
40	Prospective observational study: Fast ripple localization delineates the epileptogenic zone. Clinical Neurophysiology, 2019, 130, 2144-2152.	0.7	26
41	Visual and semi-automatic non-invasive detection of interictal fast ripples: A potential biomarker of epilepsy in children with tuberous sclerosis complex. Clinical Neurophysiology, 2018, 129, 1458-1466.	0.7	46
42	Facilitation of kindling epileptogenesis by chronic stress may be mediated by intestinal microbiome. Epilepsia Open, 2018, 3, 290-294.	1.3	66
43	Hypothalamic Hamartoma With Infantile Spasms: Case Report With Surgical Treatment. Seminars in Pediatric Neurology, 2018, 26, 115-118.	1.0	4
44	Interrater reliability in visual identification of interictal highâ€frequency oscillations on electrocorticography and scalp <scp>EEG</scp> . Epilepsia Open, 2018, 3, 127-132.	1.3	21
45	A comparison of levetiracetam and phenobarbital for the treatment of neonatal seizures associated with hypoxic–ischemic encephalopathy. Epilepsy and Behavior, 2018, 88, 212-217.	0.9	40
46	Amantadine: A new treatment for refractory electrical status epilepticus in sleep. Epilepsy and Behavior, 2018, 84, 74-78.	0.9	47
47	Successful use of pure cannabidiol for the treatment of super-refractory status epilepticus. Epilepsy & Behavior Case Reports, 2018, 10, 141-144.	1.5	12
48	Galanin contributes to monoaminergic dysfunction and to dependent neurobehavioral comorbidities of epilepsy. Experimental Neurology, 2017, 289, 64-72.	2.0	14
49	Risk of vigabatrinâ€associated brain abnormalities on <scp>MRI</scp> in the treatment of infantile spasms is doseâ€dependent. Epilepsia, 2017, 58, 674-682.	2.6	53
50	Inherent vulnerabilities in monoaminergic pathways predict the emergence of depressive impairments in an animal model of chronic epilepsy. Epilepsia, 2017, 58, e116-e121.	2.6	15
51	Intraoperative fast ripples independently predict postsurgical epilepsy outcome: Comparison with other electrocorticographic phenomena. Epilepsy Research, 2017, 135, 79-86.	0.8	27
52	Regulation of kindling epileptogenesis by hippocampal Tollâ€like receptors 2. Epilepsia, 2017, 58, e122-e126.	2.6	4
53	WONOEP appraisal: Biomarkers of epilepsyâ€associated comorbidities. Epilepsia, 2017, 58, 331-342.	2.6	39
54	Recognition of Infantile Spasms Is Often Delayed: The ASSIST Study. Journal of Pediatrics, 2017, 190, 215-221.e1.	0.9	36

#	Article	IF	CITATIONS
55	Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy. New England Journal of Medicine, 2017, 377, 1630-1638.	13.9	412
56	Kindling epileptogenesis and panic-like behavior: Their bidirectional connection and contribution to epilepsy-associated depression. Epilepsy and Behavior, 2017, 77, 33-38.	0.9	20
57	Sex-Specific Life Course Changes in the Neuro-Metabolic Phenotype of Glut3 Null Heterozygous Mice: Ketogenic Diet Ameliorates Electroencephalographic Seizures and Improves Sociability. Endocrinology, 2017, 158, 936-949.	1.4	20
58	Prevention of infantile spasms relapse: Zonisamide and topiramate provide no benefit. Epilepsia, 2016, 57, 1280-1287.	2.6	19
59	Effects of selective serotonin and norepinephrine reuptake inhibitors on depressive―and impulsiveâ€like behaviors and on monoamine transmission in experimental temporal lobe epilepsy. Epilepsia, 2016, 57, 506-515.	2.6	33
60	Common Mechanisms Underlying Epileptogenesis and the Comorbidities of Epilepsy. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a022798.	2.9	33
61	Deconstructing tolerance with clobazam. Neurology, 2016, 87, 1806-1812.	1.5	15
62	Prospective and "live―fast ripple detection and localization in the operating room: Impact on epilepsy surgery outcomes in children. Epilepsy Research, 2016, 127, 344-351.	0.8	21
63	A lack of clinically apparent vision loss among patients treated with vigabatrin with infantile spasms: The UCLA experience. Epilepsy and Behavior, 2016, 57, 29-33.	0.9	20
64	Early Infantile Epileptic Encephalopathy with a de novo variant in ZEB2 identified by exome sequencing. European Journal of Medical Genetics, 2016, 59, 70-74.	0.7	8
65	Limited efficacy of the ketogenic diet in the treatment of highly refractory epileptic spasms. Seizure: the Journal of the British Epilepsy Association, 2016, 35, 59-64.	0.9	17
66	Cytokine-dependent bidirectional connection between impaired social behavior and susceptibility to seizures associated with maternal immune activation in mice. Epilepsy and Behavior, 2015, 50, 40-45.	0.9	14
67	The Ketogenic Diet as Broad-Spectrum Treatment for Super-Refractory Pediatric Status Epilepticus. Journal of Child Neurology, 2015, 30, 259-266.	0.7	49
68	Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox–Gastaut syndrome. Epilepsy and Behavior, 2015, 47, 138-141.	0.9	189
69	Hypsarrhythmia assessment exhibits poor interrater reliability: A threat to clinical trial validity. Epilepsia, 2015, 56, 77-81.	2.6	93
70	Autism-Like Behavior in BTBR Mice Is Improved by Electroconvulsive Therapy. Neurotherapeutics, 2015, 12, 657-666.	2.1	13
71	Clinical considerations in transitioning patients with epilepsy from clonazepam to clobazam: a case series. Journal of Medical Case Reports, 2014, 8, 429.	0.4	9
72	Treatment of infantile spasms with very high dose prednisolone before high dose adrenocorticotropic hormone. Epilepsia, 2014, 55, 103-107.	2.6	65

#	Article	IF	CITATIONS
73	Behavioral impairments in rats with chronic epilepsy suggest comorbidity between epilepsy and attention deficit/hyperactivity disorder. Epilepsy and Behavior, 2014, 31, 267-275.	0.9	51
74	Neuroprotective and antiepileptogenic effects of combination of anti-inflammatory drugs in the immature brain. Journal of Neuroinflammation, 2013, 10, 30.	3.1	74
75	Maternal immune activation promotes hippocampal kindling epileptogenesis in mice. Annals of Neurology, 2013, 74, 11-19.	2.8	79
76	Sociodemographic changes over 25 years of pediatric epilepsy surgery at UCLA. Journal of Neurosurgery: Pediatrics, 2013, 11, 250-255.	0.8	10
77	Time to pediatric epilepsy surgery is related to disease severity and nonclinical factors. Neurology, 2013, 80, 1231-1239.	1.5	45
78	Time to Pediatric Epilepsy Surgery Is Longer and Developmental Outcomes Lower for Government Compared With Private Insurance. Neurosurgery, 2013, 73, 152-157.	0.6	23
79	Pediatric Epilepsy Surgery. Neurosurgery, 2012, 71, 985-993.	0.6	30
80	GABAA Receptor Physiology and Its Relationship to the Mechanism of Action of the 1,5-Benzodiazepine Clobazam. CNS Drugs, 2012, 26, 229-244.	2.7	101
81	Neurocognitive profiles in children with epilepsy. Epilepsia, 2012, 53, 2156-2163.	2.6	62
82	Interleukin-1beta Causes Fluoxetine Resistance in an Animal Model of Epilepsy-Associated Depression. Neurotherapeutics, 2012, 9, 477-485.	2.1	80
83	The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: Implications for clinical use. Epilepsia, 2012, 53, 425-436.	2.6	60
84	The mechanism of action of retigabine (ezogabine), a firstâ€inâ€class K ⁺ channel opener for the treatment of epilepsy. Epilepsia, 2012, 53, 412-424.	2.6	261
85	Pharmacologic Treatment of Intractable Epilepsy in Children: A Syndrome-Based Approach. Seminars in Pediatric Neurology, 2011, 18, 171-178.	1.0	9
86	Plasticity of Presynaptic and Postsynaptic Serotonin 1A Receptors in an Animal Model of Epilepsy-Associated Depression. Neuropsychopharmacology, 2011, 36, 1305-1316.	2.8	39
87	Understanding Therapeutic Equivalence in Epilepsy. CNS Spectrums, 2010, 15, 112-123.	0.7	12
88	Comorbidity between epilepsy and depression: Role of hippocampal interleukin-1β. Neurobiology of Disease, 2010, 37, 461-467.	2.1	99
89	Inflammation enhances epileptogenesis in the developing rat brain. Neurobiology of Disease, 2010, 40, 303-310.	2.1	78
90	Hypoxicâ€ischemic brain injury exacerbates neuronal apoptosis and precipitates spontaneous seizures in glucose transporter isoform 3 heterozygous null mice. Journal of Neuroscience Research, 2010, 88, 3386-3398.	1.3	26

#	Article	IF	CITATIONS
91	Inflammation induced by LPS enhances epileptogenesis in immature rat and may be partially reversed by IL1RA. Epilepsia, 2010, 51, 34-38.	2.6	128
92	Evaluation of developmentâ€specific targets for antiepileptogenic therapy using rapid kindling. Epilepsia, 2010, 51, 39-42.	2.6	28
93	Comorbidity between epilepsy and depression: Experimental evidence for the involvement of serotonergic, glucocorticoid, and neuroinflammatory mechanisms. Epilepsia, 2010, 51, 110-114.	2.6	79
94	Neurobiology of depression as a comorbidity of epilepsy. Epilepsia, 2010, 51, 81-81.	2.6	13
95	Clinical profile of vigabatrin as monotherapy for treatment of infantile spasms. Neuropsychiatric Disease and Treatment, 2010, 6, 731.	1.0	23
96	Language and brain volumes in children with epilepsy. Epilepsy and Behavior, 2010, 17, 402-407.	0.9	14
97	Suicidality and brain volumes in pediatric epilepsy. Epilepsy and Behavior, 2010, 18, 286-290.	0.9	42
98	Elevated plasma corticosterone level and depressive behavior in experimental temporal lobe epilepsy. Neurobiology of Disease, 2009, 34, 457-461.	2.1	130
99	Assessment and surgical outcomes for mild type I and severe type II cortical dysplasia: A critical review and the UCLA experience. Epilepsia, 2009, 50, 1310-1335.	2.6	345
100	Bumetanide inhibits rapid kindling in neonatal rats. Epilepsia, 2009, 50, 2117-2122.	2.6	77
101	Frontal and temporal volumes in Childhood Absence Epilepsy. Epilepsia, 2009, 50, 2466-2472.	2.6	96
102	Language in pediatric epilepsy. Epilepsia, 2009, 50, 2397-2407.	2.6	67
103	Obstacles to mental health care in pediatric epilepsy: Insight from parents. Epilepsy and Behavior, 2009, 14, 360-366.	0.9	16
104	A multicenter, outpatient, open-label study to evaluate the dosing, effectiveness, and safety of topiramate as monotherapy in the treatment of epilepsy in clinical practice. Epilepsy and Behavior, 2009, 15, 506-512.	0.9	13
105	Anticonvulsant effects of the selective melatonin receptor agonist ramelteon. Epilepsy and Behavior, 2009, 16, 52-57.	0.9	49
106	Paroxysmal fast activity: An interictal scalp EEG marker of epileptogenesis in children. Epilepsy Research, 2008, 82, 99-106.	0.8	54
107	Antiepileptogenic and antiictogenic effects of retigabine under conditions of rapid kindling: An ontogenic study. Epilepsia, 2008, 49, 1777-1786.	2.6	39
108	Childhood absence epilepsy: Behavioral, cognitive, and linguistic comorbidities. Epilepsia, 2008, 49, 1838-1846.	2.6	313

#	Article	IF	CITATIONS
109	Amygdala volume and psychopathology in childhood complex partial seizures. Epilepsy and Behavior, 2008, 13, 212-217.	0.9	20
110	Dealing with epilepsy: Parents speak up. Epilepsy and Behavior, 2008, 13, 131-138.	0.9	35
111	Thought disorder and frontotemporal volumes in pediatric epilepsy. Epilepsy and Behavior, 2008, 13, 593-599.	0.9	15
112	Depression after status epilepticus: behavioural and biochemical deficits and effects of fluoxetine. Brain, 2008, 131, 2071-2083.	3.7	170
113	Chapter 12 Teratogenicity of Antiepileptic Drugs. International Review of Neurobiology, 2008, 83, 215-225.	0.9	7
114	Does adjunctive lamotrigine provide improved control of primary generalized tonic–clonic seizures in children?. Nature Clinical Practice Neurology, 2007, 3, 306-307.	2.7	1
115	Kindling epileptogenesis in immature rats leads to persistent depressive behavior. Epilepsy and Behavior, 2007, 10, 377-383.	0.9	81
116	Frontal and temporal volumes in children with epilepsy. Epilepsy and Behavior, 2007, 10, 470-476.	0.9	16
117	Unmet mental health needs in pediatric epilepsy: Insights from providers. Epilepsy and Behavior, 2007, 11, 401-408.	0.9	25
118	Do Seizures Affect the Developing Brain? Lessons From the Laboratory. Journal of Child Neurology, 2007, 22, 21S-29S.	0.7	41
119	Age-dependent Effects of Topiramate on the Acquisition and the Retention of Rapid Kindling. Epilepsia, 2007, 48, 765-773.	2.6	22
120	Status Epilepticus Triggers Caspase-3 Activation and Necrosis in the Immature Rat Brain. Epilepsia, 2007, 48, 1203-1206.	2.6	37
121	Inflammation Exacerbates Seizureâ€induced Injury in the Immature Brain. Epilepsia, 2007, 48, 27-34.	2.6	79
122	Inflammation modifies status epilepticusâ€induced hippocampal injury during development. Epilepsia, 2007, 48, 16-18.	2.6	5
123	Regulation of Kindling Epileptogenesis by Hippocampal Galanin Type 1 and Type 2 Receptors: The Effects of Subtype-Selective Agonists and the Role of G-Protein-Mediated Signaling. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 700-708.	1.3	88
124	Thought disorder: A developmental disability in pediatric epilepsy. Epilepsy and Behavior, 2006, 8, 726-735.	0.9	43
125	Status Epilepticus: Danse Macabre in a Ballet of Subunits. Epilepsy Currents, 2006, 6, 102-105.	0.4	2
126	The Utility of Testing Pentylenetetrazol Threshold. Epilepsia, 2006, 47, 662-663.	2.6	8

#	Article	IF	CITATIONS
127	Children with ESES: Variability in the Syndrome. Epilepsy Research, 2006, 70, 248-258.	0.8	151
128	Hippocampal volume in childhood complex partial seizures. Epilepsy Research, 2006, 72, 57-66.	0.8	10
129	Status Epilepticus: Electrical Stimulation Models. , 2006, , 449-464.		8
130	Treatment of Experimental Status Epilepticus in Immature Rats: Dissociation Between Anticonvulsant and Antiepileptogenic Effects. Pediatric Research, 2006, 59, 237-243.	1.1	81
131	In vivo interaction between serotonin and galanin receptors types 1 and 2 in the dorsal raphe: implication for limbic seizures. Journal of Neurochemistry, 2005, 95, 1495-1503.	2.1	56
132	Galanin and Epilepsy: Promises with Nuances \hat{a} € $ $. Epilepsy Currents, 2005, 5, 78-80.	0.4	1
133	Status Epilepticus and Frequent Seizures: Incidence and Clinical Characteristics in Pediatric Epilepsy Surgery Patients. Epilepsia, 2005, 46, 1950-1954.	2.6	30
134	Reduced Anesthetization during the Intracarotid Amobarbital (Wada) Test in Patients Taking Carbonic Anhydrase-Inhibiting Medications. Epilepsia, 2005, 46, 236-243.	2.6	37
135	Neonatal seizures. Neurology, 2005, 64, 776-777.	1.5	85
136	Social competence in pediatric epilepsy: insights into underlying mechanisms. Epilepsy and Behavior, 2005, 6, 218-228.	0.9	73
137	Neuroprotection in epilepsy: The Holy Grail of antiepileptogenic therapy. Epilepsy and Behavior, 2005, 7, 1-2.	0.9	6
138	Postnatal hypoxic-ischemic brain injury alters mechanisms mediating neuronal glucose transport. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2004, 286, R273-R282.	0.9	50
139	Mechanisms of Action for the Commonly Used Antiepileptic Drugs: Relevance to Antiepileptic Drug-Associated Neurobehavioral Adverse Effects. Journal of Child Neurology, 2004, 19, S6-S14.	0.7	27
140	Psychopathology and Pediatric Complex Partial Seizures: Seizure-related, Cognitive, and Linguistic Variables. Epilepsia, 2004, 45, 1273-1281.	2.6	115
141	Initial treatment of epilepsy with antiepileptic drugs. Neurology, 2004, 63, S30-9.	1.5	33
142	Development of Temporal Lobe Epilepsy in 21-day-old Rats. Epilepsia, 2003, 44, 872-872.	2.6	1
143	Treatment Strategies for Myoclonic Seizures and Epilepsy Syndromes with Myoclonic Seizures. Epilepsia, 2003, 44, 27-37.	2.6	32
144	Animal Model of Cortical Dysplasia for Screening Candidate AEDs. Epilepsy Currents, 2003, 3, 6-7.	0.4	8

#	Article	IF	CITATIONS
145	Environmental Factors Influence Neurogenesis and Modify the Cognitive Outcome after Status Epilepticus. Epilepsy Currents, 2003, 3, 8-10.	0.4	Ο
146	Levetiracetam: its use in partial-onset seizure. Expert Review of Neurotherapeutics, 2003, 3, 751-760.	1.4	0
147	Age-Dependent Differences in Flurothyl-Induced c-fos and c-jun mRNA Expression in the Mouse Brain. Developmental Neuroscience, 2002, 24, 294-299.	1.0	8
148	Seizure-induced neuronal death in the immature brain. Progress in Brain Research, 2002, 135, 335-353.	0.9	63
149	Insulin-responsive glucose transporters—GLUT8 and GLUT4 are expressed in the developing mammalian brain. Molecular Brain Research, 2002, 107, 157-165.	2.5	83
150	Differential induction of p53 in immature and adult rat brain following lithium–pilocarpine status epilepticus. Brain Research, 2002, 928, 187-193.	1.1	30
151	Immunohistochemical study of p53-associated proteins in rat brain following lithium–pilocarpine status epilepticus. Brain Research, 2002, 929, 129-138.	1.1	39
152	Short-Term Plasticity of Hippocampal Neuropeptides and Neuronal Circuitry in Experimental Status Epilepticus. Epilepsia, 2002, 43, 20-29.	2.6	47
153	Epileptogenesis During Development: Injury, Circuit Recruitment, and Plasticity. Epilepsia, 2002, 43, 47-53.	2.6	23
154	Epileptogenesis After Self-Sustaining Status Epilepticus. Epilepsia, 2002, 43, 74-80.	2.6	49
155	Visual Field Defects and Other Ophthalmological Disturbances Associated with Vigabatrin. Drug Safety, 2001, 24, 385-404.	1.4	31
156	Measures of Psychopathology in Children With Complex Partial Seizures and Primary Generalized Epilepsy With Absence. Journal of the American Academy of Child and Adolescent Psychiatry, 2001, 40, 907-914.	0.3	121
157	Epileptogenesis after status epilepticus reflects age- and model-dependent plasticity. Annals of Neurology, 2000, 48, 580-589.	2.8	130
158	Granule Cell Neurogenesis After Status Epilepticus in the Immature Rat Brain. Epilepsia, 2000, 41, S53-S56.	2.6	90
159	Self-Sustaining Status Epilepticus: A Condition Maintained by Potentiation of Glutamate Receptors and by Plastic Changes in Substance P and Other Peptide Neuromodulators. Epilepsia, 2000, 41, S134-S143.	2.6	50
160	Modulation of Hippocampal Excitability and Seizures by Galanin. Journal of Neuroscience, 2000, 20, 6276-6281.	1.7	206
161	Epileptogenesis after status epilepticus reflects age- and model-dependent plasticity. , 2000, 48, 580.		9
162	Ontogeny of Self-Sustaining Status epilepticus. Developmental Neuroscience, 1999, 21, 345-351.	1.0	17

#	Article	IF	CITATIONS
163	The Pharmacologic Basis of Antiepileptic Drug Action. Epilepsia, 1999, 40, 1471-1483.	2.6	162
164	Is the devil we know the lesser of two evils?. Neurology, 1999, 52, 1537-1537.	1.5	24
165	Self-sustaining status epilepticus after brief electrical stimulation of the perforant path. Brain Research, 1998, 801, 251-253.	1.1	104
166	Time-dependent decrease in the effectiveness of antiepileptic drugs during the course of self-sustaining status epilepticus. Brain Research, 1998, 814, 179-185.	1.1	227
167	Patterns of Status Epilepticus-Induced Neuronal Injury during Development and Long-Term Consequences. Journal of Neuroscience, 1998, 18, 8382-8393.	1.7	389
168	Galanin Modulation of Seizures and Seizure Modulation of Hippocampal Galanin in Animal Models of Status Epilepticus. Journal of Neuroscience, 1998, 18, 10070-10077.	1.7	172
169	Induction of brain derived neurotrophic factor mRNA by seizures in neonatal and juvenile rat brain. Molecular Brain Research, 1997, 44, 219-228.	2.5	55
170	Vigabatrin. Seminars in Pediatric Neurology, 1997, 4, 43-50.	1.0	13
171	GABA metabolism during status epilepticus in the developing rat brain. Developmental Brain Research, 1997, 98, 60-64.	2.1	30
172	Serum neuron-specific enolase is a marker for neuronal damage following status epilepticus in the rat. Epilepsy Research, 1997, 28, 129-136.	0.8	97
173	Developmental outcomes in children receiving resection surgery for medically intractable infantile spasms. Developmental Medicine and Child Neurology, 1997, 39, 430-440.	1.1	148
174	Hemispherectomy for intractable seizures in children: a report of 58 cases. Child's Nervous System, 1996, 12, 376-384.	0.6	174
175	Pathophysiological Mechanisms of Brain Damage from Status Epilepticus. Epilepsia, 1993, 34, S37-53.	2.6	425
176	Surgery for Intractable Infantile Spasms: Neuroimaging Perspectives. Epilepsia, 1993, 34, 764-771.	2.6	275
177	Infantile spasms: II. Lenticular nuceli and brain stem activation on positron emission tomography. Annals of Neurology, 1992, 31, 212-219.	2.8	259
178	Octanoic Acid Inhibits Astrocyte Volume Control: Implications for Cerebral Edema in Reye's Syndrome. Journal of Neurochemistry, 1989, 52, 1197-1202.	2.1	14
179	Energy-dependent volume regulation in primary cultured cerebral astrocytes. Journal of Cellular Physiology, 1986, 128, 209-215.	2.0	108